The efficacy and safety of selective granulocyte and monocyte apheresis for inflammatory bowel disease: A meta-analysis

Liu, Zhenfei; Jiang, Xue-Liang; Sun, Chengcheng

doi:10.1016/j.ejim.2016.08.028

Cited by 5 publications

(1 citation statement)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In 2013 prospective cohort of 35 patients of CD showed 63% clinical remission with no significant complications reported, forming an argument for GMA in patients with active CD. Moreover, a 2016 meta-analysis on GMA for IBD pooled three RCTs on CD with 362 subjects[ 40 ]. The remission rate in CD was non-significant (OR, 1.10, 95%CI: 0.51–2.34), making use of GMA for patients with CD uncertain.…”

Section: Introductionmentioning

confidence: 99%

Apheresis: A cell-based therapeutic tool for the inflammatory bowel disease

Yasmin¹,

Najeeb²,

Naeem³

et al. 2022

WJCC

View full text Add to dashboard Cite

Inflammatory Bowel Disease (IBD) is a hallmark of leukocyte infiltration, followed by the release of cytokines and interleukins. Disease progression to Ulcerative Colitis (UC) or Crohn’s Disease (CD) remained largely incurable. The genetic and environmental factors disrupt enteral bacteria in the gut, which hampers the intestinal repairing capability of damaged mucosa. Commonly practiced pharmacological therapies include 5-aminosalicylic acid with corticosteroids and tumor necrosis factor (TNF)-α. New interventions such as CDP571 and TNF-blocking RDP58 report the loss of patient response. This review discusses the non-pharmacologic selective granulocyte–monocyte-apheresis (GMA) and leukocytapheresis (LCAP) that have been proposed as treatment modalities that reduce mortality. GMA, an extracorporeal vein-to-vein technique, presents a strong safety profile case for its use as a viable therapeutic option compared to GMA's conventional medication safety profile. GMA reported minimal to no side effects in the pediatric population and pregnant women. Numerous studies report the efficacious nature of GMA in UC patients, whereas data on CD patients is insufficient. Its benefits outweigh the risks and are emerging as a favored non-pharmacological treatment option. On the contrary, LCAP uses a general extracorporeal treatment that entraps leukocytes and suppresses cytokine release. It has been deemed more efficacious than conventional drug treatments, the former causing better disease remission, and maintenance. Patients with UC/CD secondary to complications have responded well to the treatment. Side effects of the procedure have remained mild to moderate, and there is little evidence of any severe adverse event occurring in most age groups. LCAP decreases the dependence on steroids and immunosuppressive therapies for IBD. The review will discuss the role of GMA and LCAP.

show abstract

Section: Introductionmentioning

confidence: 99%